01 (Image 01)
Nifedipine Tablet, Extended Release
Product Images NDC 50090-6203
View Photos of Packaging, Regulatory Labels, and Product Appearance
Product Visual Gallery
This gallery contains 4 technical images submitted to the FDA as part of the official labeling for Nifedipine (NDC 50090-6203). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.
As provided by A-s Medication Solutions, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.
Product Images & Figures Index
02 (Image 02)
This text appears to describe the adverse effects of Nifedipine extended-release tablets compared to a placebo, as reported in a study with 707 participants. The most common adverse effects reported were constipation, nausea, and headaches, with the incidence rate being higher in the Nifedipine group as compared to the placebo group. The reliability of the output is uncertain as there appears to be missing data points and certain values are not given for each of the symptoms.*
03 (Image 03)
This is a table showing the percentage of patients who experienced different adverse effects while taking Nifedipine Capsules compared to a placebo. The adverse effects included dizziness, lightheadedness, giddiness, flushing, heat sensation, headache, weakness, nausea, heartburn, muscle cramps, tremor, peripheral edema, nervousness, mood changes, palpitations, dyspnea, cough, wheezing, nasal congestion, and sore throat.*
Label Image (Lbl500906203)
* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.
